Agilent Technologies, Inc. (NYSE:A) Shares Sold by Cantillon Capital Management LLC

Cantillon Capital Management LLC trimmed its stake in shares of Agilent Technologies, Inc. (NYSE:AFree Report) by 2.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,298,930 shares of the medical research company’s stock after selling 98,574 shares during the period. Agilent Technologies accounts for 3.0% of Cantillon Capital Management LLC’s holdings, making the stock its 14th biggest position. Cantillon Capital Management LLC owned about 1.15% of Agilent Technologies worth $489,825,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Crewe Advisors LLC raised its stake in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after purchasing an additional 101 shares during the period. Livelsberger Financial Advisory acquired a new stake in Agilent Technologies in the third quarter valued at $28,000. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies in the 2nd quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Agilent Technologies in the third quarter valued at about $31,000. Finally, Fortitude Family Office LLC raised its position in Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after buying an additional 95 shares during the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Price Performance

A stock opened at $126.92 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The firm has a market cap of $36.47 billion, a price-to-earnings ratio of 26.33, a PEG ratio of 5.59 and a beta of 1.07. The company’s fifty day simple moving average is $138.50 and its 200 day simple moving average is $137.92. Agilent Technologies, Inc. has a 12-month low of $112.39 and a 12-month high of $155.35.

Agilent Technologies (NYSE:AGet Free Report) last announced its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the previous year, the business earned $1.43 EPS. The firm’s revenue was down 5.6% compared to the same quarter last year. On average, analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.74%. Agilent Technologies’s payout ratio is presently 19.50%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on A. UBS Group raised their price target on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Citigroup lifted their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Barclays lifted their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 15th. Bank of America lifted their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Finally, TD Cowen boosted their target price on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $144.36.

Check Out Our Latest Research Report on Agilent Technologies

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 7.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,995 shares of company stock valued at $1,739,510 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

About Agilent Technologies

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Stories

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.